vs
Side-by-side financial comparison of Altimmune, Inc. (ALT) and ANAVEX LIFE SCIENCES CORP. (AVXL). Click either name above to swap in a different company.
ANAVEX LIFE SCIENCES CORP. is the larger business by last-quarter revenue ($1.1M vs $26.0K, roughly 41.5× Altimmune, Inc.). On growth, Altimmune, Inc. posted the faster year-over-year revenue change (420.0% vs -22.6%). Over the past eight quarters, Altimmune, Inc.'s revenue compounded faster (128.0% CAGR vs -21.6%).
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, vaccines, and peptide-based therapies. Its pipeline covers infectious disease prevention, liver disease treatments, and metabolic disorder therapies, serving global biopharmaceutical and healthcare markets while advancing candidates through clinical trials.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical firm focused on developing novel small molecule therapeutics for neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Rett syndrome and Parkinson’s disease. It operates mainly across North America and European markets, targeting patients with high unmet medical needs.
ALT vs AVXL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $26.0K | $1.1M |
| Net Profit | — | $-5.7M |
| Gross Margin | — | — |
| Operating Margin | — | -628.5% |
| Net Margin | — | -526.5% |
| Revenue YoY | 420.0% | -22.6% |
| Net Profit YoY | -18.0% | 53.1% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.0K | $1.1M | ||
| Q3 25 | $5.0K | $999.0K | ||
| Q2 25 | $5.0K | $1.1M | ||
| Q1 25 | $5.0K | $1.2M | ||
| Q4 24 | $5.0K | $1.4M | ||
| Q3 24 | $5.0K | $1.8M | ||
| Q2 24 | $5.0K | $1.8M | ||
| Q1 24 | $5.0K | $1.8M |
| Q4 25 | — | $-5.7M | ||
| Q3 25 | $-19.0M | $-9.8M | ||
| Q2 25 | $-22.1M | $-13.2M | ||
| Q1 25 | $-19.6M | $-11.2M | ||
| Q4 24 | — | $-12.1M | ||
| Q3 24 | $-22.8M | $-11.6M | ||
| Q2 24 | $-24.6M | $-12.2M | ||
| Q1 24 | $-24.4M | $-10.5M |
| Q4 25 | — | -628.5% | ||
| Q3 25 | -417180.0% | -1085.5% | ||
| Q2 25 | -458440.0% | -1345.0% | ||
| Q1 25 | -436300.0% | -1034.1% | ||
| Q4 24 | — | -975.0% | ||
| Q3 24 | -495340.0% | -810.9% | ||
| Q2 24 | -534900.0% | -813.1% | ||
| Q1 24 | -535880.0% | -718.9% |
| Q4 25 | — | -526.5% | ||
| Q3 25 | -380280.0% | -983.7% | ||
| Q2 25 | -442920.0% | -1231.9% | ||
| Q1 25 | -391500.0% | -925.3% | ||
| Q4 24 | — | -868.8% | ||
| Q3 24 | -456900.0% | -660.2% | ||
| Q2 24 | -492800.0% | -680.1% | ||
| Q1 24 | -487880.0% | -600.6% |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $-0.21 | $-0.11 | ||
| Q2 25 | $-0.27 | $-0.16 | ||
| Q1 25 | $-0.26 | $-0.13 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | $-0.32 | $-0.14 | ||
| Q2 24 | $-0.35 | $-0.14 | ||
| Q1 24 | $-0.34 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $273.5M | $131.7M |
| Total DebtLower is stronger | $34.3M | — |
| Stockholders' EquityBook value | $224.9M | $126.6M |
| Total Assets | $279.9M | $133.0M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $273.5M | $131.7M | ||
| Q3 25 | $210.8M | $102.6M | ||
| Q2 25 | $183.1M | $101.2M | ||
| Q1 25 | $149.8M | $115.8M | ||
| Q4 24 | $131.9M | $120.8M | ||
| Q3 24 | $139.4M | $132.2M | ||
| Q2 24 | $164.9M | $138.8M | ||
| Q1 24 | $182.0M | $139.4M |
| Q4 25 | $34.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $224.9M | $126.6M | ||
| Q3 25 | $185.6M | $94.9M | ||
| Q2 25 | $161.4M | $91.0M | ||
| Q1 25 | $142.2M | $99.8M | ||
| Q4 24 | $123.5M | $110.9M | ||
| Q3 24 | $133.4M | $120.3M | ||
| Q2 24 | $152.5M | $129.8M | ||
| Q1 24 | $172.9M | $135.0M |
| Q4 25 | $279.9M | $133.0M | ||
| Q3 25 | $218.4M | $103.8M | ||
| Q2 25 | $190.3M | $102.4M | ||
| Q1 25 | $157.3M | $117.1M | ||
| Q4 24 | $139.3M | $124.0M | ||
| Q3 24 | $147.9M | $135.6M | ||
| Q2 24 | $173.3M | $141.5M | ||
| Q1 24 | $188.4M | $144.5M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.5M | $-7.2M |
| Free Cash FlowOCF − Capex | $-67.5M | — |
| FCF MarginFCF / Revenue | -259792.3% | — |
| Capex IntensityCapex / Revenue | 42.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-67.5M | $-7.2M | ||
| Q3 25 | $-11.9M | $-8.6M | ||
| Q2 25 | $-19.4M | $-12.5M | ||
| Q1 25 | $-16.8M | $-5.9M | ||
| Q4 24 | $-79.8M | $-12.1M | ||
| Q3 24 | $-27.1M | $-6.7M | ||
| Q2 24 | $-18.1M | $-5.2M | ||
| Q1 24 | $-16.4M | $-11.7M |
| Q4 25 | $-67.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -259792.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 42.3% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
